Jeffrey W. Albers, Director at Kymera Therapeutics, Inc. (KYMR), sold 10,000 shares at $90.30 ($898K) on 2025-12-08, disclosed to the SEC on 2025-12-08.
Scheduled sale ($898k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $89.32 | 2,748 | $245K | 27.3% |
| 2 | $89.32 | 2,748 | $245K | 27.3% |
| 3 | $90.30 | 2,252 | $203K | 22.7% |
| 4 | $90.30 | 2,252 | $203K | 22.7% |
| Total | $89.76 avg | 10,000 | $898K | 100% |
| Filing → |
| KYMR | SELL | 2025-06-03 | $311K | — | Filing → |
| BPMC | SELL | 2025-05-29 | $572K | — | Filing → |
| BPMC | SELL | 2025-03-17 | $1.0M | — | Filing → |